This inventor holds 1 USPTO granted patent. Top assignee: Sail Biomedicines. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Maxence Bos: Innovator in Pharmaceutical Chemistry
Introduction
Maxence Bos is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific biological pathways. His work is focused on addressing critical health issues, including cancer and immune response disorders.
Latest Patents
Maxence Bos holds a patent for "Fused imidazole derivatives as AHR antagonists." This patent encompasses compounds of formulae (I)-(VI) and their pharmaceutically acceptable salts. The disclosure details pharmaceutical compositions that include these compounds, methods for their preparation, and intermediate compounds useful for their synthesis. The patent aims to provide methods for treating or preventing diseases, particularly those associated with dysregulated immune responses or aberrant AHR signaling.
Career Highlights
Maxence Bos is currently associated with Sail Biomedicines, where he applies his expertise in pharmaceutical development. His innovative approach to drug design has positioned him as a key figure in the industry. His work is characterized by a commitment to advancing therapeutic options for patients suffering from complex diseases.
Collaborations
Throughout his career, Maxence has collaborated with talented professionals, including Alessandra Bartolozzi and John Robert Proudfoot. These collaborations have fostered a dynamic research environment, enhancing the potential for groundbreaking discoveries in the field.
Conclusion
Maxence Bos exemplifies the spirit of innovation in pharmaceutical chemistry. His contributions through patents and collaborations continue to pave the way for advancements in medical treatments. His work is a testament to the impact that dedicated inventors can have on healthcare and society.